A genome-wide exome association study has identified the transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 variant encoding an E167K substitution as a genetic determinant of hepatic steatosis in nonalcoholic fatty liver disease (NAFLD). The role of this variant across a spectrum of liver diseases and pathologies and on serum lipids comparing viral hepatitis to NAFLD, and viral load in chronic viral hepatitis, and its intrahepatic molecular signature, have not been well characterized. We undertook detailed analyses in 3,260 subjects with viral and non-viral liver diseases and in healthy controls. Serum inflammatory markers and hepatic expression of TM6SF2 and genes regulating lipid metabolism were assessed in a subset with chronic hepatitis C (CHC). The rs58542926 T allele was more prevalent in 502 NAFLD patients than controls (p=0.02), but not different in cohorts with CHC (n = 2,023) and CHB (n = 507). The T allele was associated with alterations in serum lipids and hepatic steatosis in all diseases, and with reduced hepatic TM6SF2 and MTTP expression expression. Interestingly, the substitution was associated with reduced CHC viral load, but increased HBV-DNA. The rs58542926 T allele had no effect on inflammation, impacted on ≥F2 fibrosis in CHC and NAFLD assessed cross-sectionally (OR: 1.39 (95% CI = 1.04-1.87 and OR: 1.62, 95% CI: 1.03-2.52, respectively, p<0.03 for both), but had no effect on fibrosis progression in 1174 patients with CHC and a known duration of infection. We conclude that the TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and MTTP expression and differentially impacts CHC and CHB viral load, while effects on fibrosis are marginal.
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INTRODUCTION
Ectopic lipid accumulation associated with the increasing worldwide prevalence of obesity ( 1 ) is linked with tissue meta-inflammation ( 2 ), resulting in organ dysfunction, excess morbidity and mortality ( 3 ). In this context, hepatic rather than visceral fat deposition is more tightly linked with the metabolic complications of obesity ( 4 ) and it is therefore not surprising that steatosis is now the most commonly observed histological abnormality across a spectrum of liver diseases ( 5 ). The heritability of steatosis is therefore of considerable interest, with a landmark genome-wide association study (GWAS) ( 6 ) and subsequent reports ( 7 ) demonstrating unequivocal evidence that a non-synonymous single-nucleotide polymorphism (SNP) in patatinlike phospholipase domain containing 3 (PNPLA3) rs738409 is associated not only with steatosis severity, but with the extent of fibrosis in NAFLD ( 8 ). More recently, in 7176 individuals of European ancestry, a GWAS meta-analysis in NAFLD using 2.4 million SNPs imputed to HapMap, identified additional common variants at 5 loci containing multiple genes (NCAN/TM6SF2/CILP2/PBX4) that impacts steatosis ( 7 ). A subsequent genome-wide exome association study with functional analysis ( 9 ) identified an rs58542926 C>T variant in the transmembrane 6 superfamily member 2 (TM6SF2) gene, which encodes an amino acidic substitution (E167K) as the causative variant for the GWAS signal. The impact of TM6SF2 rs58542926 as a determinant of liver fat in NAFLD is well-established ( 10, 11, 12 ). While there is evidence suggesting a role for this variant in NAFLD-associated liver fibrosis, this finding is not unequivocal ( 10, 11, 12, 13, 14 ) , and is debatable in the case of CHC ( 15, 16 ). There is no data on the role of rs58542926 in chronic hepatitis B (CHB).
With regard to the metabolic consequences of harboring the rs58542926 T allele, an association with lower levels of serum total cholesterol, LDL-cholesterol (LDL-C) and triglycerides (TG), and protection from atherosclerosis and cardiovascular events in NAFLD Based on these considerations, the aims of the present study were to clarify the influence of the TM6SF2 rs58542926 variant on the metabolic and histological features of liver diseases, comparing viral hepatitis to NAFLD, to explore effects on viral load and thirdly to investigate the impact of carriage of the T allele on the expression of hepatic TM6SF2 and genes modulating liver lipid accumulation.
Methods

Patient cohort
The study comprised 3,260 consecutive subjects from the International Liver Disease 
Clinical and laboratory assessment
A detailed description of the baseline data collected at the time of liver biopsy and methods to estimate the duration of infection is provided in supplementary methods. Data included demographic parameters, alcohol intake, and routine laboratory variables including metabolic parameters.
Genotyping
Genotyping for TM6SF2 rs58542926 and PNPLA3 rs738409 was contracted to the Australian Genome Research Facility (AGRF; QLD, Australia). Samples were genotyped using the Sequenom MassARRAY system and iPLEX Gold chemistry. Further genotyping for both SNPs (n=1150) was undertaken using the TaqMan SNP genotyping allelic discrimination method (Applied Biosystems, Foster City, CA, USA). All genotyping was blinded to clinical variables.
Liver Histopathology
Liver histopathology was scored according to METAVIR ( 28 ( 32 ) and summarized in the supplementary methods. Serum TNF-α, soluble tumor necrosis factor receptor 2 (sTNFR2) and IL-6 in these patients were measured by sandwich enzyme-linked immunosorbent assay (ELISA).
Statistical Analysis
Statistical methods are detailed in the supplementary methods. All tests were two-tailed and p values <0.05 were considered significant.
Results
Patient characteristics
The study comprised 3,260 consecutive subjects including 2,023 with CHC, 507 with As regards the metabolic profile, subjects with the TT genotype had significantly lower total cholesterol, LDL-C and TG, while paradoxically having significantly higher BMI and a trend to higher HOMA-IR. The median of ALT, AST, GGT and ALP levels, and platelet counts were not significantly different between rs58542926 genotypes ( Table 1) . Similar results were observed when comparing CT/TT vs. CC (data not shown). For the purposes of comparison, the association of PNPLA3 rs738409 with the same variables was investigated. Apart from the fact that subjects with rs738409 GG genotype were significantly younger and had lower fasting blood glucose level, compared to subjects with CG and CC, no other significant associations were observed (Supplementary Table 3 ).
Association between the TM6SF2 variant and histological features in the cohort with CHC
We next assessed in the CHC cohort, the association between TM6SF2 rs58542926 and histological features including steatosis, features of steatohepatitis (in 112 subjects), inflammation and fibrosis. Table 4 ).
We explored the association of rs58542926 with the severity of steatosis by subdividing the cohort according to absent/mild steatosis (S0-S1) compared to moderate/severe steatosis (S2-S3). In this analysis, rs58542926 was associated with the severity of steatosis (OR: 1.14, 95%CI: Table 5 ). The adjusted OR for having significant fibrosis (≥F2) was 1.39 (95% CI: 1.04-1.87, p=0.02) for the T allele, and with cirrhosis (>F4) was 1.82 (95% CI: 1.01-3.28, p=0.04) ( Table 2) .
Association between the TM6SF2 variant and fibrosis progression
Given the inherent biases in cross sectional analyses, the lack of impact of TM6SF2 rs58542926 genotype on hepatic inflammation, the principal driver of liver fibrosis, and the modest impact on fibrosis stage (absent in multivariate linear regression and present by multivariate logistic regression), we undertook further analysis in 1,174 patients with CHC and a known duration of infection, allowing us to assess the relationship with fibrosis progression. The baseline characteristics of the cohort were similar among subjects included and not included in the fibrosis progression sub-analysis (Supplementary Table 6 ). The OR of rs58542926 for having fast FPR was 1.31 (95% CI: 1.08-2.97, p=0.03), while after adjustment, the T allele was not independently associated with FPR (p= 0.5) (Supplementary Table 7) .
For further confirmation, we assessed fibrosis progression using Cox-proportional hazards to address the concern that FPR may not be constant over time ( There was no evidence of interaction between rs58542926 and rs738409 on any histological features (steatosis, inflammation and fibrosis) (data not shown).
In sum, the TM6SF2 rs58542926 T allele was associated with a modest risk of hepatic steatosis in CHC, being more profound in subjects with non-genotype 3 infection. There was no effect of the T allele on inflammation, while an effect on fibrosis stage was at best, modest, with no effect on fibrosis progression. The effect of the TM6SF2 rs58542926 T allele was independent of PNPLA3 738409.
Relationships between rs58542926 genotype and hepatic gene expression
There was a significant relationship between carriage of the rs58542926 T allele and lower TM6SF2 mRNA expression (p=0. 001, Figure 2 B) . Expression of SREBP1c, FAS and ACOX1 mRNA, as markers of lipid synthesis and oxidation, were not significantly different according to rs58542926 genotype. As expected however, serum TG was significantly lower in subjects with the rs58542926 CT/TT than CC genotype (Figure 2 C) . The expression of MTTP, a key protein involved in TG packaging and export was significantly lower in liver from subjects with the T allele ( Figure 2C ). These results suggest that in CHC, carriers of the T allele for rs58542926 have reduced TM6SF2 and MTTP expression, concomitant with reduced serum TG levels.
Other chronic liver diseases
Chronic hepatitis B
The characteristics of 507 Chinese patients with CHB are summarized in Supplementary Table   10 ), and PNPLA3 rs738409 showed no association with either inflammation or fibrosis.
Again, as noted in other liver diseases cohorts, subjects with the T allele had lower serum TG and LDL-C, but this was significant only for the latter (p=0.008). Interestingly, in contrast to what was observed in CHC, patients with CHB had higher HBV-DNA levels (p=0.04) (Supplementary Table 11 Table 12 ).
NAFLD
The characteristics of 502 Caucasian patients with NAFLD are summarized in 
Supplementary
Discussion
We clarified the influence of the TM6SF2 rs58542926 variant on the metabolic and histological features of viral hepatitis as compared to that in NAFLD. The most noteworthy finding was that the E167K substitution had a consistent effect on the serum metabolic profile and the predisposition to hepatic steatosis, rather than to hepatic inflammation and fibrosis across all three diseases. This effect was independent and not additive to the influence of the PNPLA3 . This is also consistent with another recent study demonstrating that the rs58542926 T allele is associated with decreased gene and protein expression in liver of NAFLD patients ( 12 ).
Of interest, in the CHC sub-cohort, we show that MTTP expression, required for VLDL assembly and maturation was reduced with carriage of the T allele, while the expression of genes involved in lipid synthesis and oxidation (SREBP1c, FAS and Acox1 mRNA) were unaffected.
This human data is consistent with, and adds to recent observations from Tm6sf2 overexpression and knockdown in mice and in vitro studies demonstrating that TM6SF2 is a key modulator of TG-rich lipoproteins and apolipoprotein B (apoB) ( 9, 18 ). In humans, TG is delivered to adipose tissues by intestinally-derived chylomicrons and by hepatic VLDL synthesis ( 35 ). Notably, both liver and intestine express the highest levels of TM6SF2 ( 9,18 ). MTTP is absolutely required for VLDL assembly and maturation ( 36 ), catalyzing the transport of triglyceride, cholesteryl ester and phospholipids to the nascent apoB molecule, that is required for the assembly and secretion of VLDL and low-density lipoproteins (LDLs) ( 37 ). MTTP is found in abundance on the luminal side of the ER and in the liver, intestine, and heart ( 38 ), and thus it is of interest that a recent study using confocal microscopy observed localization of green fluorescent protein-tagged TM6SF2 to the ER of 2 human hepatoma cell lines (Huh7 and HepG2) ( 18 ). In that study, knockdown of TM6SF2 in both cell lines had no effect on the expression of APOB or MTTP, however whether MTTP expression is altered based on TM6SF2 genotype was not tested.
Of particular interest is the significant and opposite association between the TM6SF2 variant and HCV and HBV viral load, with the T allele associated with lower HCV-RNA levels but higher HBV-DNA. The association remained significant (p=0.001 with CHC and p=0.03
with CHB) after controlling for the main confounders. Although our analyses do not allow for a mechanistic explanation, it is consistent with previous reports from population based studies and experimental models indicating that HCV-RNA levels correlate positively, while HBV-DNA levels correlate inversely with serum TG ( [21] [22] [23] The TM6SF2 rs58542926 MAF of 0.07 in our Chinese patients with CHB was similar to that observed in Caucasian populations, and in other Han Chinese population cohorts ( 13 ).
In our three cohorts, we were able to undertake robust analysis to assess the role of the E167K substitution on the more controversial aspects of liver histology, namely inflammation and fibrosis. The TM6SF2 rs58542926 variant had no detectable effect on inflammation in all three chronic liver diseases, whether by histological grade, liver enzymes (ALT or AST) or in a subset with CHC, the levels of serum inflammatory markers (TNF-α, IL-6 and sTNFR2). Thus, clearly, if the E167K substitution in TM6SF2 rs58542926 contributes to liver fibrosis, as has been suggested ( 10, 15 ) it is likely mediated by a process other than hepatic necroinflammation.
To confirm or refute a role for the E167K substitution in TM6SF2 on liver fibrosis, the cohort of nearly 1200 patients with CHC and a known duration of infection had us uniquely positioned to assess fibrosis progression, compared to all previous reports. In this analysis, rs58542926 genotype had no effect on fibrosis progression assessed using either stage-constant fibrosis progression rates or Cox regression to model the time taken for significant fibrosis (≥ F2) or cirrhosis (≥ F4) to develop. Likewise, in cross sectional analyses of the total cohort with CHC (n=2023), the rs58542926 T allele was not associated with fibrosis stage in adjusted multivariate linear regression analysis, while it only showed an association with ≥F2 fibrosis Thus, in sum, our analyses indicates that the E167K substitution in TM6SF2 rs58542926
has marginal if any effect on fibrosis in chronic viral hepatitis, and no effect on inflammation or fibrosis progression. In NAFLD, perhaps because steatosis occurs in the context of systemic metabolic dysregulation and oxidant stress from intra-hepatic toxic lipid species such as unesterified free fatty acids and ceramides ( 47 ), the TM6SF2 rs58542926 variant more consistently amplifies and contributes to fibrosis. It should be noted, that the present analysis is unable to dissect whether the effect of the TM6SF2 variant on fibrosis is direct or indirect through its association with metabolic derangements.
Unfortunately, data on viral clearance was not available in order to investigate the clinical relevance of our observations regarding TM6SF2 rs58542926 with HCV and HBV viral load.
Further, it should be acknowledged that population stratification was not assessed in detail.
However, all participants with CHC and NAFLD were of Caucasian ancestry and all CHB patients were Chinese. It should be noted that population structure is more critical when studying rare variants ( 48 ), while rs58542926 does not fit into this category (MAF=0.07), and we did not observe any difference in MAF between the different centres.
In conclusion, this is the first study to compare the diverse impacts of the rs58542926 E167K variant in TM6SF2 on the metabolic and histological features of metabolic and viral liver disease. We demonstrate that the E167K substitution in TM6SF2 is associated with altered serum lipoproteins and susceptibility to hepatic steatosis in viral and non viral chronic liver disease, and with reduced hepatic MTTP expression in the HCV cohort. Though, the TM6SF2 rs58542926 minor allele influenced fibrosis in NAFLD, it had no discernable effects on liver inflammation, and perhaps only a minor influence on hepatic fibrosis, in chronic viral hepatitis. Importantly, the variant is associated with viral load, in opposing directions in CHC as compared to CHB, likely modulated by the differential effects of hepatic lipid metabolism and export, on the HBV and HCV virus life cycle. No difference was observed in other genetic models. 
